MAPT and Alzheimer disease: Tau vaccines in human trials include AADvac1, whose antigen is amino acids 294–305 of the 4R form of tau, and ACI-35, whose antigen is a peptide containing pS396 and pS404.52 AADvac1 induced an immune response against recombinant pathological tau in 29 of 30 people tested and is now in a phase II trial in AD.52 ACI-35 was tested in 24 AD patients in a phase 1b trial, and the related vaccine, ACI-35.030, will be tested in a phase 1b/2a trial.52,53